Open AccessThis article is
- freely available
Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis
Research Centre for Reproductive Health, School of Paediatrics and Reproductive Health, Robinson Institute, University of Adelaide, Adelaide, South Australia 5005, Australia
Research Centre for Infectious Diseases, School of Molecular Biosciences, University of Adelaide, South Australia 5005, Australia
Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia
* Author to whom correspondence should be addressed.
Received: 30 November 2010; in revised form: 28 January 2011 / Accepted: 29 January 2011 / Published: 31 January 2011
Abstract: There is increasing evidence to suggest that extracellular matrix (ECM) components play an active role in tumor progression and are an important determinant for the growth and progression of solid tumors. Tumor cells interfere with the normal programming of ECM biosynthesis and can extensively modify the structure and composition of the matrix. In ovarian cancer alterations in the extracellular environment are critical for tumor initiation and progression and intra-peritoneal dissemination. ECM molecules including versican and hyaluronan (HA) which interacts with the HA receptor, CD44, have been shown to play critical roles in ovarian cancer metastasis. This review focuses on versican, HA, and CD44 and their potential as therapeutic targets for ovarian cancer.
Keywords: extracellular matrix; hyaluronan; versican; CD44; adhesion; metastasis
Citations to this Article
Cite This Article
MDPI and ACS Style
Ween, M.P.; Oehler, M.K.; Ricciardelli, C. Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. Int. J. Mol. Sci. 2011, 12, 1009-1029.
Ween MP, Oehler MK, Ricciardelli C. Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. International Journal of Molecular Sciences. 2011; 12(2):1009-1029.
Ween, Miranda P.; Oehler, Martin K.; Ricciardelli, Carmela. 2011. "Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis." Int. J. Mol. Sci. 12, no. 2: 1009-1029.